A version of this story originally appeared in The Readout, STAT’s biotech newsletter. Sign up here.
Dr. David Hung has had a distinguished career in biotech, presiding over the development of a blockbuster cancer drug and flipping a company for $14 billion. But the last act, in which he led an Alzheimer’s disease startup through a catastrophic failure, is one from which he’d like to move on.
Which is perhaps why Hung scrubbed it from his LinkedIn profile.
About the Author Reprints
NELO data will be spectacular
Its from the ARNA labs
GPCR technology is 3 for 3 all best in class
Ralenepig
Entresimod
Belviq
Soon Apd 371 Non opioid pain Non addictive
He left too soon
Jumping on Axovant ship he proved that the first time around he got either unbelievably lucky, or he was just a street smart. Either way, he must be a mediocre scientist/physician.